Your browser doesn't support javascript.
loading
Identification of bicyclic hexafluoroisopropyl alcohol sulfonamides as retinoic acid receptor-related orphan receptor gamma (RORγ/RORc) inverse agonists. Employing structure-based drug design to improve pregnane X receptor (PXR) selectivity.
Gong, Hua; Weinstein, David S; Lu, Zhonghui; Duan, James J-W; Stachura, Sylwia; Haque, Lauren; Karmakar, Ananta; Hemagiri, Hemalatha; Raut, Dhanya Kumar; Gupta, Arun Kumar; Khan, Javed; Camac, Dan; Sack, John S; Pudzianowski, Andrew; Wu, Dauh-Rurng; Yarde, Melissa; Shen, Ding-Ren; Borowski, Virna; Xie, Jenny H; Sun, Huadong; D'Arienzo, Celia; Dabros, Marta; Galella, Michael A; Wang, Faye; Weigelt, Carolyn A; Zhao, Qihong; Foster, William; Somerville, John E; Salter-Cid, Luisa M; Barrish, Joel C; Carter, Percy H; Dhar, T G Murali.
Afiliação
  • Gong H; Bristol-Myers Squibb, Research and Development, Princeton, NJ 08543-4000, United States.
  • Weinstein DS; Bristol-Myers Squibb, Research and Development, Princeton, NJ 08543-4000, United States.
  • Lu Z; Bristol-Myers Squibb, Research and Development, Princeton, NJ 08543-4000, United States.
  • Duan JJ; Bristol-Myers Squibb, Research and Development, Princeton, NJ 08543-4000, United States.
  • Stachura S; Bristol-Myers Squibb, Research and Development, Princeton, NJ 08543-4000, United States.
  • Haque L; Bristol-Myers Squibb, Research and Development, Princeton, NJ 08543-4000, United States.
  • Karmakar A; Bristol-Myers Squibb-Biocon Research Center, Bangalore, India.
  • Hemagiri H; Bristol-Myers Squibb-Biocon Research Center, Bangalore, India.
  • Raut DK; Bristol-Myers Squibb-Biocon Research Center, Bangalore, India.
  • Gupta AK; Bristol-Myers Squibb-Biocon Research Center, Bangalore, India.
  • Khan J; Bristol-Myers Squibb, Research and Development, Princeton, NJ 08543-4000, United States.
  • Camac D; Bristol-Myers Squibb, Research and Development, Princeton, NJ 08543-4000, United States.
  • Sack JS; Bristol-Myers Squibb, Research and Development, Princeton, NJ 08543-4000, United States.
  • Pudzianowski A; Bristol-Myers Squibb, Research and Development, Princeton, NJ 08543-4000, United States.
  • Wu DR; Bristol-Myers Squibb, Research and Development, Princeton, NJ 08543-4000, United States.
  • Yarde M; Bristol-Myers Squibb, Research and Development, Princeton, NJ 08543-4000, United States.
  • Shen DR; Bristol-Myers Squibb, Research and Development, Princeton, NJ 08543-4000, United States.
  • Borowski V; Bristol-Myers Squibb, Research and Development, Princeton, NJ 08543-4000, United States.
  • Xie JH; Bristol-Myers Squibb, Research and Development, Princeton, NJ 08543-4000, United States.
  • Sun H; Bristol-Myers Squibb, Research and Development, Princeton, NJ 08543-4000, United States.
  • D'Arienzo C; Bristol-Myers Squibb, Research and Development, Princeton, NJ 08543-4000, United States.
  • Dabros M; Bristol-Myers Squibb, Research and Development, Princeton, NJ 08543-4000, United States.
  • Galella MA; Bristol-Myers Squibb, Research and Development, Princeton, NJ 08543-4000, United States.
  • Wang F; Bristol-Myers Squibb, Research and Development, Princeton, NJ 08543-4000, United States.
  • Weigelt CA; Bristol-Myers Squibb, Research and Development, Princeton, NJ 08543-4000, United States.
  • Zhao Q; Bristol-Myers Squibb, Research and Development, Princeton, NJ 08543-4000, United States.
  • Foster W; Bristol-Myers Squibb, Research and Development, Princeton, NJ 08543-4000, United States.
  • Somerville JE; Bristol-Myers Squibb, Research and Development, Princeton, NJ 08543-4000, United States.
  • Salter-Cid LM; Bristol-Myers Squibb, Research and Development, Princeton, NJ 08543-4000, United States.
  • Barrish JC; Bristol-Myers Squibb, Research and Development, Princeton, NJ 08543-4000, United States.
  • Carter PH; Bristol-Myers Squibb, Research and Development, Princeton, NJ 08543-4000, United States.
  • Dhar TGM; Bristol-Myers Squibb, Research and Development, Princeton, NJ 08543-4000, United States. Electronic address: murali.dhar@bms.com.
Bioorg Med Chem Lett ; 28(2): 85-93, 2018 01 15.
Article em En | MEDLINE | ID: mdl-29233651
ABSTRACT
We disclose the optimization of a high throughput screening hit to yield benzothiazine and tetrahydroquinoline sulfonamides as potent RORγt inverse agonists. However, a majority of these compounds showed potent activity against pregnane X receptor (PXR) and modest activity against liver X receptor α (LXRα). Structure-based drug design (SBDD) led to the identification of benzothiazine and tetrahydroquinoline sulfonamide analogs which completely dialed out LXRα activity and were less potent at PXR. Pharmacodynamic (PD) data for compound 35 in an IL-23 induced IL-17 mouse model is discussed along with the implications of a high Ymax in the PXR assay for long term preclinical pharmacokinetic (PK) studies.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies Limite: Animals / Humans / Male Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies Limite: Animals / Humans / Male Idioma: En Ano de publicação: 2018 Tipo de documento: Article